StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
444
This month
4
This week
1
This year
27
Publishing Date
2023 - 11 - 22
3
2023 - 10 - 16
3
2023 - 10 - 11
3
2023 - 05 - 08
4
2023 - 04 - 20
3
2023 - 04 - 18
3
2023 - 01 - 10
2
2023 - 01 - 09
2
2023 - 01 - 06
2
2022 - 12 - 15
2
2022 - 12 - 09
2
2022 - 12 - 05
2
2022 - 11 - 28
2
2022 - 11 - 07
3
2022 - 10 - 31
2
2022 - 10 - 10
2
2022 - 10 - 03
4
2022 - 09 - 05
2
2022 - 08 - 24
2
2022 - 08 - 08
2
2022 - 07 - 19
5
2022 - 07 - 05
2
2022 - 06 - 14
3
2022 - 06 - 13
5
2022 - 06 - 06
4
2022 - 05 - 16
2
2022 - 05 - 05
2
2022 - 04 - 06
2
2022 - 03 - 14
2
2022 - 03 - 01
3
2022 - 02 - 28
2
2022 - 02 - 14
2
2022 - 01 - 25
2
2021 - 12 - 24
2
2021 - 12 - 13
2
2021 - 11 - 22
2
2021 - 11 - 04
3
2021 - 11 - 02
3
2021 - 10 - 28
2
2021 - 09 - 30
2
2021 - 09 - 27
3
2021 - 09 - 24
2
2021 - 09 - 23
2
2021 - 09 - 18
2
2021 - 09 - 17
2
2021 - 09 - 02
2
2021 - 08 - 16
2
2021 - 08 - 05
2
2021 - 08 - 03
2
2021 - 07 - 26
2
2021 - 07 - 16
3
2021 - 07 - 14
2
2021 - 07 - 09
2
2021 - 06 - 25
2
2021 - 05 - 05
3
2021 - 04 - 23
4
2021 - 04 - 20
2
2021 - 04 - 19
2
2021 - 04 - 13
2
2021 - 03 - 16
2
Sector
Administrative and support and waste management and remediation services
1
Consumer services
2
Electronic technology
1
Finance
4
Health services
2
Health technology
444
Manufacturing
14
N/a
6
Professional, scientific, and technical services
9
Technology services
1
Tags
Alliances
9
Antibody
18
Application
17
Approval
41
Asco
7
Asia
8
Atopic dermatitis
9
Baricitinib
9
Biocapital
37
Business
8
Cancer
57
Car-t
11
Cel
9
Cell
11
Cell carcinoma
7
China
33
Chinese
25
Clinical-trials-phase-iii
12
Collaboration
19
Companies
24
Dermatitis
11
Designation
15
Disease
16
Drug
33
Earnings
21
Events
17
Expected
9
Fda
23
Financial
21
Financial results
13
Granted
7
Growth
34
Ibi351
9
Ibi362
12
Market
54
Medical
8
Meeting
16
N/a
279
New drug
9
Obesity
10
Pancreatic
7
People
10
Phase 1
14
Phase 2
19
Phase 3
23
Positive
15
Presentation
11
Report
13
Research
19
Results
72
Review
8
Study
37
T-cell
11
Therapeutics
20
Therapy
37
Treatment
77
Trial
28
Tumors
8
Tyvyt
9
Update
12
Entities
Abbvie inc.
17
Acadia pharmaceuticals inc.
4
Adc therapeutics sa
13
Agenus inc.
3
Agios pharmaceuticals, inc.
11
Alkermes plc
5
Alnylam pharmaceuticals, inc.
14
Alpine immune sciences, inc.
3
Amgen inc.
12
Arcus biosciences, inc.
4
Astellas pharma inc
6
Astrazeneca plc
3
Athenex, inc.
3
Atreca, inc.
3
Aveo pharmaceuticals, inc.
18
Beigene, ltd.
12
Biogen inc.
4
Biomea fusion inc
3
Biontech se
6
Blueprint medicines corporation
23
Briacell therapeutics corp.
4
Bristol-myers squibb company
24
Cellectis s.a.
3
Clovis oncology, inc.
19
Eli lilly and company
207
Epizyme, inc.
21
Exelixis, inc.
14
Glaxosmithkline plc
7
Global blood therapeutics, inc.
5
Illumina, inc.
10
Incyte corporation
444
Ionis pharmaceuticals, inc.
7
Iovance biotherapeutics, inc.
5
Ironwood pharmaceuticals, inc.
4
Jazz pharmaceuticals plc
5
Johnson & johnson
22
Karyopharm therapeutics inc.
18
Leap therapeutics, inc.
4
Macrogenics, inc.
11
Merus n.v.
14
Morphosys ag
28
Neurocrine biosciences, inc.
4
Novartis ag
21
Pfizer, inc.
14
Ptc therapeutics, inc.
4
Regeneron pharmaceuticals, inc.
18
Rigel pharmaceuticals, inc.
10
Sage therapeutics, inc.
4
Sanofi
121
Sarepta therapeutics, inc.
4
Seagen inc.
4
Syndax pharmaceuticals, inc.
5
Syros pharmaceuticals, inc.
11
Takeda pharmaceutical company limited
16
Ultragenyx pharmaceutical inc.
6
United therapeutics corporation
4
Urogen pharma ltd.
4
Verastem, inc.
10
Xencor, inc.
37
Y-mabs therapeutics, inc.
18
Symbols
AAPL
1194
ABB
1423
ABBV
1023
ABLZF
1162
ABT
1784
ACN
600
AMGN
742
ARVL
4285
AZN
664
BDX
796
BMY
662
BNPQF
1764
BNPQY
1764
CSCO
895
DHR
785
ERIC
1607
F
641
FNCTF
7171
FRBA
595
GE
915
GLAXF
657
GOOG
1274
GOOGL
1273
GSK
883
HON
1779
HUBS
1400
IBM
654
INTC
954
IT
590
JNJ
4571
LLY
1708
LTUM
970
LYV
717
MDT
1285
MMM
938
MS
4279
MSFT
1199
MT
588
NOC
588
NOK
898
NOKBF
972
NVO
631
NVS
1241
NVSEF
1031
ORCL
1157
PCRFF
650
PCRFY
650
PFE
692
PHG
962
PPRUF
1126
PPRUY
1127
SAP
1474
SAPGF
1228
SNOW
794
SNY
4532
SNYNF
3590
TEVJF
630
TMO
1621
VZ
1211
XYF
674
Exchanges
Amex
2
Nasdaq
444
Nyse
269
Crawled Date
2023 - 11 - 22
3
2023 - 10 - 16
3
2023 - 10 - 11
3
2023 - 05 - 08
4
2023 - 04 - 20
3
2023 - 04 - 18
3
2022 - 12 - 05
2
2022 - 11 - 28
2
2022 - 11 - 07
3
2022 - 10 - 31
2
2022 - 10 - 10
2
2022 - 10 - 03
4
2022 - 09 - 05
2
2022 - 08 - 24
2
2022 - 08 - 08
2
2022 - 07 - 20
2
2022 - 07 - 19
4
2022 - 07 - 05
2
2022 - 06 - 29
2
2022 - 06 - 14
3
2022 - 06 - 13
5
2022 - 06 - 06
4
2022 - 05 - 16
2
2022 - 05 - 05
2
2022 - 04 - 06
2
2022 - 03 - 14
2
2022 - 03 - 01
3
2022 - 02 - 28
2
2022 - 02 - 24
2
2022 - 02 - 14
2
2022 - 01 - 26
2
2021 - 12 - 24
2
2021 - 12 - 13
2
2021 - 11 - 22
2
2021 - 11 - 04
3
2021 - 11 - 02
3
2021 - 10 - 28
2
2021 - 09 - 30
2
2021 - 09 - 27
3
2021 - 09 - 24
2
2021 - 09 - 23
2
2021 - 09 - 22
2
2021 - 09 - 18
2
2021 - 09 - 17
2
2021 - 09 - 02
2
2021 - 08 - 16
2
2021 - 08 - 05
2
2021 - 08 - 03
2
2021 - 07 - 26
2
2021 - 07 - 16
3
2021 - 07 - 14
2
2021 - 07 - 09
2
2021 - 06 - 25
2
2021 - 06 - 02
2
2021 - 05 - 05
3
2021 - 04 - 23
4
2021 - 04 - 20
2
2021 - 04 - 19
2
2021 - 04 - 13
2
2021 - 03 - 16
2
Crawled Time
00:00
42
00:01
1
00:20
6
01:00
73
02:00
4
03:00
6
04:20
3
05:00
4
06:00
4
07:00
3
09:00
7
10:00
5
11:00
12
11:36
1
12:00
26
12:09
1
12:15
4
12:20
3
12:30
4
13:00
18
13:13
1
13:15
3
13:20
2
13:30
7
13:50
1
14:00
13
14:15
2
14:20
5
14:30
2
14:58
1
15:00
15
15:15
1
15:20
1
15:30
2
16:00
28
16:20
1
17:00
16
17:37
1
18:00
11
18:04
1
18:17
1
18:26
1
18:31
2
18:33
1
18:40
1
18:42
1
19:00
8
19:11
2
19:32
1
19:52
1
20:00
11
20:59
1
21:00
36
22:00
23
23:00
13
Source
investor.alkermes.com
4
mindmed.co
2
www.biospace.com
165
www.fda.gov
18
www.globenewswire.com
25
www.precisionbiosciences.com
1
www.preludetx.com
1
www.prnewswire.com
228
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
INCY
save search
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published:
2024-04-15
(Crawled : 22:00)
- prnewswire.com
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-0.39%
|
O:
-0.17%
H:
1.41%
C:
-0.22%
t-cell
for
therapy
growth
market
Incyte to Report First Quarter Financial Results - April 11, 2024
Published:
2024-04-11
(Crawled : 21:00)
- biospace.com/
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-3.24%
|
O:
0.62%
H:
1.17%
C:
-0.76%
first
report
financial
results
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Published:
2024-04-01
(Crawled : 12:30)
- globenewswire.com
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-7.14%
|
O:
-0.6%
H:
0.0%
C:
-0.58%
license
collaboration
asia
agreement
china
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published:
2024-04-01
(Crawled : 17:00)
- biospace.com/
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-7.14%
|
O:
-0.6%
H:
0.0%
C:
-0.58%
license
collaboration
asia
agreement
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published:
2024-03-27
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-7.85%
|
O:
-0.26%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
-3.63%
|
O:
0.49%
H:
0.84%
C:
-0.07%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-6.77%
|
O:
1.06%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-5.89%
|
O:
-0.09%
H:
1.42%
C:
1.1%
ibi310
first
cancer
colon
therapy
study
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published:
2024-03-13
(Crawled : 23:00)
- biospace.com/
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
-4.76%
|
O:
-0.23%
H:
0.0%
C:
0.0%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-6.97%
|
O:
-0.07%
H:
0.09%
C:
-0.7%
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-17.02%
|
O:
-0.66%
H:
4.19%
C:
3.13%
MOR
|
News
|
$18.03
0.45%
0.44%
400K
|
Health Technology
|
-1.21%
|
O:
0.22%
H:
0.22%
C:
-0.93%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-10.3%
|
O:
0.03%
H:
1.47%
C:
-0.72%
year
update
financial
results
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Published:
2024-03-12
(Crawled : 00:00)
- prnewswire.com
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-5.1%
|
O:
0.01%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-12.45%
|
O:
-0.12%
H:
0.3%
C:
-2.29%
preclinical
meeting
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published:
2024-03-05
(Crawled : 06:00)
- prnewswire.com
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-2.4%
|
O:
1.17%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-10.88%
|
O:
0.4%
H:
0.38%
C:
-1.77%
lung
cancer
treatment
therapeutics
china
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Published:
2024-03-04
(Crawled : 14:30)
- biospace.com/
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-9.87%
|
O:
0.34%
H:
0.89%
C:
0.79%
meeting
growing
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
Published:
2024-02-29
(Crawled : 12:30)
- globenewswire.com
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-16.98%
|
O:
2.68%
H:
2.22%
C:
-1.92%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-11.27%
|
O:
0.38%
H:
0.0%
C:
-3.07%
minjuvi
brazil
therapeutics
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Published:
2024-02-28
(Crawled : 21:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
-1.44%
|
O:
-0.6%
H:
0.45%
C:
0.08%
MRUS
|
$41.01
1.74%
1.71%
410K
|
Health Technology
|
-17.23%
|
O:
2.3%
H:
0.58%
C:
-2.69%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-11.27%
|
O:
0.38%
H:
0.0%
C:
-3.07%
business
year
update
financial
results
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published:
2024-02-27
(Crawled : 23:00)
- biospace.com/
SNDX
|
$20.75
-2.49%
-2.55%
1.7M
|
Health Technology
|
-12.7%
|
O:
0.88%
H:
1.12%
C:
-0.73%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-12.08%
|
O:
0.2%
H:
1.37%
C:
0.58%
drug
disease
review
food
treatment
grants
Incyte to Present at Upcoming March 2024 Investor Conference
Published:
2024-02-15
(Crawled : 14:00)
- biospace.com/
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-8.07%
|
O:
0.35%
H:
3.06%
C:
1.51%
conference
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published:
2024-02-13
(Crawled : 19:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-7.55%
|
O:
0.14%
H:
0.35%
C:
0.07%
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
-7.75%
|
O:
-3.56%
H:
2.91%
C:
-3.34%
MOR
|
News
|
$18.03
0.45%
0.44%
400K
|
Health Technology
|
3.58%
|
O:
-0.4%
H:
0.23%
C:
-0.46%
MGNX
|
$16.12
-3.36%
-3.47%
950K
|
Health Technology
|
-6.92%
|
O:
-5.25%
H:
2.94%
C:
2.18%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-7.99%
|
O:
3.8%
H:
1.1%
C:
-1.17%
financial
Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published:
2024-02-12
(Crawled : 23:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-1.6%
|
O:
3.52%
H:
0.0%
C:
-1.18%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
12.13%
|
O:
0.06%
H:
2.34%
C:
2.29%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-13.68%
|
O:
0.37%
H:
0.74%
C:
0.28%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-7.55%
|
O:
0.14%
H:
0.35%
C:
0.07%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-7.67%
|
O:
-0.34%
H:
0.23%
C:
-1.13%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.76%
|
O:
0.7%
H:
0.0%
C:
0.0%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-2.73%
|
O:
1.22%
H:
0.07%
C:
-0.43%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
1.29%
|
O:
-0.96%
H:
1.75%
C:
1.75%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-2.99%
|
O:
-0.18%
H:
0.48%
C:
-1.91%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
-6.08%
|
O:
0.8%
H:
0.0%
C:
0.0%
ZLAB
|
$13.75
-4.65%
-4.87%
400K
|
Health Technology
|
-20.81%
|
O:
-1.15%
H:
1.03%
C:
-1.5%
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
-5.82%
|
O:
-0.28%
H:
0.49%
C:
-0.32%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-0.71%
|
O:
-0.06%
H:
0.0%
C:
0.0%
IPHA
|
$2.35
-9.27%
-10.21%
16K
|
Health Technology
|
0.39%
|
O:
-3.1%
H:
1.2%
C:
-0.8%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-7.99%
|
O:
3.8%
H:
1.1%
C:
-1.17%
BIIB
|
$192.13
-1.55%
-1.57%
1.3M
|
Health Technology
|
-20.26%
|
O:
-3.72%
H:
0.58%
C:
-3.82%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
11.16%
|
O:
-0.26%
H:
0.73%
C:
-0.36%
ARGX
|
$366.37
-1.16%
-1.18%
270K
|
Health Technology
|
-5.61%
|
O:
-2.3%
H:
1.65%
C:
0.83%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
-9.45%
|
O:
0.06%
H:
0.31%
C:
-1.4%
expansion
growth
market
Anju Software Unveils Strategies for Data-Driven Decision-Making in Clinical Research at SCOPE Orlando 2024
Published:
2024-02-08
(Crawled : 16:00)
- prnewswire.com
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-7.19%
|
O:
0.02%
H:
0.65%
C:
0.02%
software
research
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published:
2024-02-07
(Crawled : 09:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
5.92%
|
O:
0.76%
H:
4.31%
C:
2.11%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-1.42%
|
O:
1.33%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-10.75%
|
O:
-0.65%
H:
0.57%
C:
-3.21%
first
management
drug
application
china
Innovent Announces Retirement of CFO and Appointment of New CFO
Published:
2024-02-05
(Crawled : 09:00)
- prnewswire.com
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-4.46%
|
O:
-1.85%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-8.79%
|
O:
-0.6%
H:
0.81%
C:
0.1%
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Published:
2024-02-05
(Crawled : 23:00)
- biospace.com/
XNCR
|
$19.08
0.85%
0.84%
450K
|
Health Technology
|
0.96%
|
O:
-1.55%
H:
2.76%
C:
1.84%
MOR
|
News
|
$18.03
0.45%
0.44%
400K
|
Health Technology
|
62.15%
|
O:
0.99%
H:
59.84%
C:
54.47%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-8.79%
|
O:
-0.6%
H:
0.81%
C:
0.1%
monjuvi
global
commercialization
Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
Published:
2024-01-30
(Crawled : 14:00)
- biospace.com/
A
|
$134.55
-1.65%
-0.85%
2.1M
|
Health Technology
|
2.99%
|
O:
0.0%
H:
1.27%
C:
1.09%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-11.99%
|
O:
0.05%
H:
0.0%
C:
-2.02%
collaboration
companion
diagnostics
advanced
← Previous
1
2
3
4
5
6
7
8
9
…
22
23
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.